Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
News Jan 21, 2013
Kiadis Pharma B.V. announced that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product ATIR™. ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors.
The U.S. patent covers the composition of matter of a rhodamine derivative used in manufacturing ATIR™, all key steps of the manufacturing process of ATIR™ and the therapeutic use of ATIR™ to prevent graft-versus-host disease associated with allogeneic stem cell transplantations. Kiadis Pharma has previously been granted similarly broad patent protection for ATIR™ in Europe.
Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: “We are delighted about the broad patent protection for ATIR™ in the world’s largest pharmaceutical market. This broad patent protection provides a strong basis for future commercialization of ATIR™ to the benefit of patients”.
Denis-Claude Roy, MD, Professor of Hematology at the Maisonneuve-Rosemont Hospital and the University of Montreal, and Inventor, added: “ATIR™ has the potential to change the current paradigm in allogeneic stem cell transplantation for patients with advanced blood cancers. We are excited that our invention of selectively removing patient reactive cells from a stem cell donation is being developed by Kiadis Pharma to prevent graft-versus-host disease and improve patient outcome”.
Watching Stem Cells Repair Spinal Cord in Real TimeNews
Clues to the reversal of brain and spine injury.READ MORE
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE